List view / Grid view
9 March 2015 | By Edinburgh Research and Innovation
University of Edinburgh spin-out company Parkure Ltd has successfully attracted over £75,000 in crowdfunding investment through ShareIn, the technology-focussed crowdfunding firm, to develop a cure for Parkinson’s disease...
6 March 2015 | By Baxter International Inc. / SuppreMol
Acquisition includes SuppreMol's early-stage pipeline of protein therapeutics for autoimmune and allergic diseases...
6 March 2015 | By The Medical Research Council
A pioneering new combined cell-gene therapy to treat lung cancer will be tested in NHS patients this year, after receiving £2m of Biomedical Catalyst funding from the Medical Research Council...
4 March 2015 | By Retrogenix
New technology aims to reduce animal testing and improve safety testing of chemicals...
4 March 2015 | By The Institute of Cancer Research
Testing breast cancer cells for how closely they resemble stem cells could identify women with the most aggressive disease, a new study suggests...
4 March 2015 | By The Institute of Cancer Research
Changing the shape of breast cancer cells could make the disease more sensitive to treatments – even driving the body’s own inflammatory response against a tumour – a new study shows...
4 March 2015 | By Domain Therapeutics
Kaldi Pharma granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease...
4 March 2015 | By The Northern Health Science Alliance
The NHSA’s ambitious project of establishing an internationally recognised life science and healthcare economy in the North of England has been given a vital boost following funding from HEFCE...
4 March 2015 | By ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H-) colorectal cancer patients in an open label, single center trial that included 22 patients (UICC stage III or…
4 March 2015 | By Bristol-Myers Squibb Company
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales...
3 March 2015 | By Probiodrug
Strong correlation between QCs and AD pathology in human brain biopsies underlines QC-inhibition as therapeutic approach...
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
27 February 2015 | By The Institute of Cancer Research
Scientists have developed a new test which can predict the survival chances of women with breast cancer by analysing images of ‘hotspots’ where there has been a fierce immune reaction to a tumour...
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1...
26 February 2015 | By TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies...
